None
Quote | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Last: | $0.99 |
---|---|
Change Percent: | 0.0% |
Open: | $0.99 |
Close: | $0.99 |
High: | $0.99 |
Low: | $0.99 |
Volume: | 100 |
Last Trade Date Time: | 02/03/2022 04:53:25 pm |
News | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...
Message Board Posts | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Subject | By | Source | When |
---|---|---|---|
Van Leeuwenhoeck Issues Initiation of Coverage Research Report | tykundegex | investorshub | 10/18/2017 1:33:53 PM |
Addex Awarded $5.3 Million Grant from US National | tykundegex | investorshub | 10/18/2017 1:21:16 PM |
IMO, Addex has a decent possibility of a | tykundegex | investorshub | 06/08/2016 7:35:22 PM |
Orphan designation granted for Dipraglurant! Next up, | tykundegex | investorshub | 01/05/2016 1:37:58 AM |
Shares up a little on 15x volume because | tykundegex | investorshub | 08/14/2015 1:33:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Addex Pharms Ltd Ord Website:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 . Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic...